OncoMatch/Clinical Trials/NCT06054906
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
Is NCT06054906 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies sintilimab+metronomic PLOF for gastric cancer.
Treatment: sintilimab+metronomic PLOF — To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) in resectable locally advanced gastric cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Disease stage
Required: Stage CT3-4AN1-3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
No prior systemic therapy such as surgery, radiotherapy, or immunotherapy for the disease at hand
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or agents targeting CTLA-4, OX-40, CD137, etc.
Cannot have received: systemic proprietary Chinese medicines with antitumor indications or immunomodulatory drugs
Have received systemic systemic therapy with proprietary Chinese medicines with antitumor indications or immunomodulatory drugs within 2 weeks prior to the first administration of the drug
Cannot have received: systemic glucocorticoid therapy or any other form of immunosuppressive therapy
Have received systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatment
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.0x10^9/L; Platelets ≥ 80x10^9/L; Hemoglobin > 7g/dL
Kidney function
Blood creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 ml/min
Liver function
Total bilirubin ≤ 1.5 x ULN (Total bilirubin > 1.5 x ULN but direct bilirubin ≤ ULN are allowed to be enrolled); AST, ALT ≤ 2.5×ULN
Cardiac function
Myocardial enzyme profile within normal range
Adequate organ function, must meet the following laboratory specifications: 8.1 Absolute neutrophil count (ANC) ≥ 1.0x10^9/L; 8.2 Platelets ≥ 80x10^9/L; 8.3 Hemoglobin > 7g/dL; 8.4 Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Total bilirubin > 1.5 x ULN but direct bilirubin ≤ ULN are allowed to be enrolled); 8.5 AST, ALT ≤ 2.5×ULN; 8.6 Blood creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 ml/min; 8.7 INR or PT ≤ 1.5 times ULN; 8.8 TSH within normal range (Enrollment allowed if baseline TSH is outside normal range but FT4 is within normal range); 8.9 Myocardial enzyme profile within normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06054906 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT3-4AN1-3M0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages